Research and Markets (http://www.researchandmarkets.com/research/2w6n6x/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Pulmonary Fibrosis Overview
- Therapeutics Development
- Pipeline Products for Pulmonary Fibrosis - Overview
- Pipeline Products for Pulmonary Fibrosis - Comparative Analysis
- Pulmonary Fibrosis - Therapeutics under Development by Companies
- Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
- Pulmonary Fibrosis - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Pulmonary Fibrosis - Products under Development by Companies
- Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
- Pulmonary Fibrosis - Companies Involved in Therapeutics Development
- AdAlta Pty Ltd.
- Advinus Therapeutics Ltd.
- Aeolus Pharmaceuticals, Inc.
- Afferent Pharmaceuticals, Inc.
- AnaMar AB
- Angion Biomedica Corp.
- aTyr Pharma, Inc.
- Biogen, Inc.
- Bioneer Corporation
- BiOrion Technologies B.V.
- Bristol-Myers Squibb Company
- Carolus Therapeutics, Inc.
- Celgene Corporation
- Digna Biotech, S.L.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- FibroGen, Inc.
- Galapagos NV
- Galectin Therapeutics, Inc.
- GenKyoTex S.A.
- Gilead Sciences, Inc.
- HanAll Biopharma Co., Ltd.
- HEC Pharm Co., Ltd.
- Histocell S.L.
- iBio, Inc.
- IMMD Inc.
- ImmuneWorks, LLC
- Inventiva SAS
- Isarna Therapeutics GmbH
- NicOx S.A.
- Pacific Therapeutics Ltd.
- Pharmaxis Limited
- Pharmicell Co., Ltd.
- Pluristem Therapeutics Inc.
- Teva Pharmaceutical Industries Limited
For more information visit http://www.researchandmarkets.com/research/2w6n6x/pulmonary
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107006055/en/
